Department of Family Medicine, Poznan University of Medical Sciences , Poznań , Poland.
Heart Division, Royal Brompton & Harefield NHS Foundation Trust , London , UK.
Curr Med Res Opin. 2019 Oct;35(10):1687-1697. doi: 10.1080/03007995.2019.1612656. Epub 2019 Jun 17.
The aim was to assess the effect of estrogen-progestin therapy (EPT) on serum levels of uric acid (SUA) and its precursors xanthine (X) and hypoxanthine (HX), and on uric acid (UA) renal excretion in hypertensive postmenopausal women treated with an angiotensin-converting enzyme inhibitor (ACEI) or thiazide diuretic (HCTZ) (ClinicalTrials.gov identifier: NCT03921736, registered 19 April 2019). Postmenopausal women with untreated essential hypertension were recruited to the study. The control group consisted of 40 postmenopausal women with normal blood pressure. Hypertensive women were randomized to two groups: hydrochlorothiazide ( = 50) or perindopril ( = 50) and to a group receiving or not receiving EPT (EPT+/EPT-) due to vasomotor symptoms. The follow-up period was one year. Blood pressure measurements as well as blood tests for SUA and its precursors X and HX were performed at baseline and after 12 months. In hypertensive women, baseline serum X and HX were significantly higher when compared to the group of normotensive women. Treatment with HCTZ led to a statistically significant increase in SUA in the subgroup of EPT- women. In this group concentrations of X and HX increased significantly after 12 months. UA/X significantly decreased after treatment with HCTZ. Lack of EPT resulted in a decrease of renal plasma flow in the HCTZ group. However, in the HCTZ and EPT + group, SUA decreased significantly when compared to baseline. None of these unfavorable effects was observed in the ACEI group regardless of EPT. 1) EPT prevents the development of hyperuricemia during antihypertensive treatment with thiazide diuretics. 2) Arterial hypertension and menopause cause impairment of UA excretion and increase the levels of SUA and its precursors X and HX. 3) EPT reduces the risk of hyperuricemia in postmenopausal women.
目的是评估雌激素-孕激素治疗(EPT)对接受血管紧张素转换酶抑制剂(ACEI)或噻嗪类利尿剂(HCTZ)治疗的高血压绝经后妇女的血清尿酸(SUA)及其前体黄嘌呤(X)和次黄嘌呤(HX)水平以及尿酸(UA)肾排泄的影响。该研究纳入了未经治疗的原发性高血压绝经后妇女。对照组由 40 名血压正常的绝经后妇女组成。将高血压妇女随机分为两组:氢氯噻嗪( = 50)或培哚普利( = 50),并根据血管舒缩症状接受或不接受 EPT(EPT+/EPT-)。随访期为一年。在基线和 12 个月时进行血压测量以及 SUA 和其前体 X 和 HX 的血液检查。与血压正常的妇女相比,高血压妇女的基线血清 X 和 HX 明显更高。在 EPT-女性亚组中,HCTZ 治疗导致 SUA 统计学上显著增加。在该组中,X 和 HX 的浓度在 12 个月后显著增加。用 HCTZ 治疗后 UA/X 显著降低。缺乏 EPT 导致 HCTZ 组肾血浆流量减少。然而,在 HCTZ 和 EPT + 组中,与基线相比,SUA 显著降低。无论是否接受 EPT,这些不利影响都没有在 ACEI 组中观察到。1)EPT 可预防噻嗪类利尿剂降压治疗期间发生高尿酸血症。2)高血压和绝经导致 UA 排泄受损,增加 SUA 及其前体 X 和 HX 的水平。3)EPT 降低了绝经后妇女发生高尿酸血症的风险。